Apyx Medical CORP

Apyx Medical Corporation announced on July 24, 2026, the reconstitution of its Board of Directors' standing committees, including the Audit, Governance, Regulatory Compliance, and Compensation Committees.

Apyx Medical Corporation announced new clinical data published in Aesthetic Surgery Journal Open Forum demonstrating significant improvements in cellulite and skin laxity using a combination treatment approach.

Apyx Medical Corporation announced the publication of a study in Plastic and Reconstructive Surgery - Global Open, indicating Renuvion combined with liposuction leads to higher patient satisfaction and fewer revisions.

Apyx Medical Corporation announced expanded FDA 510(k) clearance for its AYON Body Contouring System to include power liposuction, a move expected to enhance market demand and streamline surgical procedures.

Apyx Medical Corporation announced first quarter 2026 financial results, reporting $12.5 million in total revenue, a 32.4% increase year-over-year, and raised its full-year revenue guidance.

Apyx Medical Corporation announced preliminary, unaudited revenue results for Q4 and full year 2025, showing significant growth in Surgical Aesthetics driven by the AYON launch.

Apyx Medical reports a 32.4% increase in Q1 2026 revenue to $12.5 million, driven by strong growth in its Surgical Aesthetics segment.

Apyx Medical Corporation reported reduced net losses and increased Surgical Aesthetics sales in Q3 2025, driven by the AYON Body Contouring System launch, while navigating OEM segment declines and ongoing litigation.

Apyx Medical Corporation reported a significant reduction in net loss for Q2 2025, driven by substantial cost-cutting measures, despite a slight revenue decline, and announced the commercial launch of its AYON Body Contouring System.

Apyx Medical's Q1 2025 results show a mixed performance with growth in the Advanced Energy segment partially offset by a decline in OEM sales, while the company implements cost-saving measures to improve profitability.

Apyx Medical Corporation's Q3 2024 results show a decrease in revenue and a net loss, prompting a restructuring and cost-saving initiative.

Apyx Medical Corporation's Q2 2024 results show a decrease in revenue and gross profit compared to the same period last year, alongside increased legal expenses and a net loss.

Apyx Medical's FY2024 results reveal a focus on cost reduction and strategic adjustments amidst market headwinds, including a revenue decrease and ongoing efforts to achieve cash-flow breakeven.

Apyx Medical Corporation's 10-K filing for 2023 highlights a year of revenue growth, strategic shifts, and ongoing efforts to navigate regulatory challenges and market dynamics.

Apyx Medical Corporation Chief Operating Officer Shawn Roman exercised 15,000 stock options in a net settlement transaction.

Director Wendy Levine was granted 50,000 stock options in Apyx Medical Corporation as part of an equity incentive.

Director Stavros G. Vizirgianakis was granted 450,000 restricted stock units in Apyx Medical Corporation.

Apyx Medical Corporation CEO Charles D. Goodwin II was granted 213,948 stock options as part of an equity incentive plan.

Apyx Medical Corporation Chief Operating Officer Shawn David Roman was granted 88,044 stock options on June 11, 2026.

Director Minnie Baylor-Henry was granted 50,000 stock options in Apyx Medical Corp as part of a standard equity incentive.

Apyx Medical Corporation has issued its 2026 proxy statement, seeking shareholder approval for a new share incentive plan and the re-election of its board of directors.

Apyx Medical Corporation announces its 2025 Annual Meeting of Stockholders, detailing proposals for director elections, auditor ratification, executive compensation, and a critical amendment to its Certificate of Incorporation tied to a credit agreement, following a year of decreased revenue and increased operating losses.

Apyx Medical Corporation will hold its 2024 Annual Meeting of Stockholders on August 8, 2024, to elect directors and ratify the company's independent auditor.

Royce & Associates LP has disclosed a beneficial ownership of 7.81% of Apyx Medical Corporation's common stock as of June 30, 2026.

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, reported a 9.99% beneficial ownership stake in Apyx Medical Corporation as of December 31, 2025.

Investment adviser Royce & Associates LP has filed an amendment to its Schedule 13G, reporting a 5.95% beneficial ownership stake in Apyx Medical Corporation.

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, has reported a beneficial ownership of 9.99% in APYX Medical Corporation's common stock as of December 31, 2024.